Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30
$1.03−0.30 (-22.56%)
Close on Nov 18, 2026Market cap $96.53MP/E –Yield –
Innate Pharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was €9.01M, down 55.2% from the year before. The highest annual figure on record is €93.95M in fiscal 2018.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €9.01M | -55.2% |
| FY2024 | Dec 31, 2024 | €20.12M | -67.4% |
| FY2023 | Dec 31, 2023 | €61.64M | +6.9% |
| FY2022 | Dec 31, 2022 | €57.67M | +133.5% |
| FY2021 | Dec 31, 2021 | €24.70M | -64.6% |
| FY2020 | Dec 31, 2020 | €69.77M | -18.3% |
| FY2019 | Dec 31, 2019 | €85.45M | -9.1% |
| FY2018 | Dec 31, 2018 | €93.95M | +113.4% |
| FY2017 | Dec 31, 2017 | €44.03M | – |
See a number that looks wrong?